Customer Service 1 (888) 261-2693
Please enter Search keyword. Advanced Search
Home About Us Resources Archive Free Reports Market Window

Morgan – and Now Goldman – Are Finally in My China Trade

By Dr. Steve Sjuggerud
Tuesday, March 14, 2017

"Goldman Joins the China-Equity Bull Party After Missing Rally," a Bloomberg headline said yesterday...
 
The investing opportunity in Chinese stocks is massive today... It's so important, I launched a new product late last year called True Wealth China Opportunities to take advantage of it.
 
Morgan Stanley was a bit late to the party, publishing a 100-plus pager called "Why We Are Bullish on China" on February 13 of this year.
 
Now Goldman Sachs is the latest to get on board. Finally, the big financial firms see the opportunity we've been writing about for months.
 
And we have more upside ahead...
 
Property stocks and bank stocks are two of our "big four" themes for investing in China right now.
 
Now Goldman is catching on... As Bloomberg reported yesterday, "Chinese banks and property stocks are seen extending gains, with Goldman lifting them to overweight and market-weight respectively."
 
Meanwhile, our top-performing China-property recommendation in China Opportunities this year is up 37% year to date. (That's only 10 weeks!) And our WORST-performing China-property stock is up nearly 20% in the same time frame.
 
Chinese bank stocks are up year to date, too... You can see this in the performance of the Global X China Financials Fund (CHIX), which is up 13% year to date as I write.
 
Chinese property stocks and bank stocks have had a strong start to the year. But if you're not invested in China yet, you definitely haven't missed it!
 
NOBODY is invested in Chinese stocks – yet. Institutional investors are more "underweight" China today than they have been in many years. "Underweight" means they don't hold enough shares in China relative to their benchmark. They need to change that – and fast.
 
You need to get your money there first.
 
I am so excited about this, I'm taking a group of subscribers over to China in June...
 
Join me if you can – so you can see for yourself what the incredible opportunity is about. We will go as far north as Beijing and as far south as Hong Kong. You will get to know my best contacts in China. It is going to be fantastic. I can't wait!
 
If you're a subscriber and you'd like more details on the trip, e-mail my colleague Dan Ostrowski at [email protected]. You can also contact him by phone at (410) 864-1783.
 
Chinese stocks are still cheap – even after the recent run-up. NOBODY is invested – yet. But big money is coming, as I've explained before.
 
Morgan Stanley and Goldman Sachs are just telling their customers now... But nobody is listening yet. There's still time for big gains...
 
Come join me in June, and get the full story firsthand!
 
I hope to see you there...
 
Good investing,
 
Steve




Further Reading:

Steve has written about the incredible opportunity in China several times in the past year... Now, the big financial firms are starting to get on board. Catch up on his bullish argument here...
 

Market Notes


NEW HIGHS FOR THIS HEALTH CARE GIANT

Another one of the world's best businesses is jumping higher...
 
Last month, we highlighted why investing in "World Dominators" is one of the safest investing strategies on the planet. These companies have great brand recognition and customer loyalty, and they sit at the top of their industries. Today, another one of these elite businesses is thriving... health care giant Johnson & Johnson (JNJ).
 
Johnson & Johnson has been a leader in consumer health care products, medical devices, and pharmaceuticals for decades. The company's brands include staples like Band-Aids, skin-care brands Neutrogena and Aveeno, Listerine mouthwash, Tylenol pain reliever, congestion-reliever Sudafed, and allergy medicine Benadryl. There's a good chance you'll find Johnson & Johnson's products somewhere in your medicine cabinet.
 
Johnson & Johnson sells everyday necessities that people will always rely on. For investors, that means big, stable returns... Over the past five years, shares are up more than 90%. And the stock just hit a new all-time high. Investing in businesses that dominate their markets continues to be a winning strategy...
 

premium teaser

Buy this company to profit in China...
 
After being beaten down over the past few years, Chinese stocks are back in an uptrend. Here's one of my favorite ways to take advantage of it...
 

Recent Articles
Legal Notices: Stansberry Research LLC (Stansberry Research) is a publishing company and the indicators, strategies, reports, articles and all other features of our products are provided for informational and educational purposes only and should not be construed as personalized investment advice. Our recommendations and analysis are based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.

 

Readers should be aware that trading stocks and all other financial instruments involves risk. Past performance is no guarantee of future results, and we make no representation that any customer will or is likely to achieve similar results.

 

Our testimonials are the words of real subscribers received in real letters, emails, and other feedback who have not been paid for their testimonials. Testimonials are printed under aliases to protect privacy, and edited for length. Their claims have not been independently verified or audited for accuracy. We do not know how much money was risked, what portion of their total portfolio was allocated, or how long they owned the security. We do not claim that the results experienced by such subscribers are typical and you will likely have different results.

 

Any performance results of our recommendations prepared by Stansberry Research are not based on actual trading of securities but are instead based on a hypothetical trading account. Hypothetical performance results have many inherent limitations. Your actual results may vary.

 

Stansberry Research expressly forbids its writers from having a financial interest in any security they recommend to our subscribers. And all Stansberry Research (and affiliated companies), employees, and agents must wait 24 hours after an initial trade recommendation is published on the Internet, or 72 hours after a direct mail publication is sent, before acting on that recommendation.

 

© 2024 Stansberry Research, LLC. | Privacy Policy| Customer Service
Stansberry Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This website may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry Research, LLC. 1125 N Charles St. Suite 500, Baltimore MD 21202.